NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Holmusk became a resident company of Johnson & Johnson Innovation, JLABS (JLABS @ NYC), a premier life science incubator program. With its residency, Holmusk is excited to interact with other resident companies and looks forward to expanding its US footprint and deepening its relationship with partners and stakeholders within the pharma/life science hub of the US east coast.
Holmusk's team at JLABS @ NYC will focus on building the world's largest real-world evidence (RWE) platform for behavioral health. This platform will incorporate the latest evidence from clinical trials and real-world data, brining insights to the point of care. Additionally, the platform will serve as a stepping stone to drive innovation among pharma companies to serve patients with unmet needs and allow quicker access to new drugs.
Holmusk is proud to be a part of JLABS @ NYC, which provides an ideal stage to interact with the life science ecosystem. "Being part of JLABS is like being part of a world class network of entrepreneurs and thought leaders - we are excited to join the conversation," said Holmusk's Founder and CEO Nawal Roy.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
About Holmusk:
Holmusk is a digital health and data science company, on a mission to build the largest Real World Evidence (RWE) platform in neuroscience and for chronic diseases. The company's goal is to transform healthcare by data driven medicine. Holmusk's proprietary modeling platform leverages scientific research and digital healthcare data to inform predictive algorithms and provide actionable insights for personalized medicine. Its innovative, scalable and cost-effective digital behavior change programs are designed to nudge people towards better health. For more information, visit: holmusk.com
Advertisement
Holmusk's team at JLABS @ NYC will focus on building the world's largest real-world evidence (RWE) platform for behavioral health. This platform will incorporate the latest evidence from clinical trials and real-world data, brining insights to the point of care. Additionally, the platform will serve as a stepping stone to drive innovation among pharma companies to serve patients with unmet needs and allow quicker access to new drugs.
Advertisement
Holmusk is proud to be a part of JLABS @ NYC, which provides an ideal stage to interact with the life science ecosystem. "Being part of JLABS is like being part of a world class network of entrepreneurs and thought leaders - we are excited to join the conversation," said Holmusk's Founder and CEO Nawal Roy.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
About Holmusk:
Holmusk is a digital health and data science company, on a mission to build the largest Real World Evidence (RWE) platform in neuroscience and for chronic diseases. The company's goal is to transform healthcare by data driven medicine. Holmusk's proprietary modeling platform leverages scientific research and digital healthcare data to inform predictive algorithms and provide actionable insights for personalized medicine. Its innovative, scalable and cost-effective digital behavior change programs are designed to nudge people towards better health. For more information, visit: holmusk.com
View original content:http://www.prnewswire.com/news-releases/holmusk-proudly-announces-residency-at-jlabs--nyc-300773601.html
SOURCE Holmusk
